Over-expression of the mitogen-activated protein kinase (MAPK) kinase (MEK)-MAPK in hepatocellular carcinoma: Its role in tumor progression and apoptosis

BMC Gastroenterology

Volumn 3, Issue , 2003, Pages

  Huynh, Hung ^a   Tuyen Nguyen, Thi Thanh ^a   Pierce Chow, Kah Hoe ^a   Tan, Puay Hoon ^a   Soo, Khee Chee ^a   Tran, Evelyne ^a  

^a SINGAPORE GENERAL HOSPITAL   (Singapore)

Author keywords

[No Author keywords available]

Indexed keywords

1,4 DIAMINO 1,4 BIS(2 AMINOPHENYLTHIO) 2,3 DICYANOBUTADIENE; 2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; 2 MORPHOLINO 8 PHENYLCHROMONE; 3 (4,5 DIMETHYL 2 THIAZOLYL) 2,5 DIPHENYLTETRAZOLIUM BROMIDE; 4 (4 FLUOROPHENYL) 2 (4 METHYLSULFINYLPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; ANTHRA[1,9 CD]PYRAZOL 6(2H) ONE; CASPASE 3; CASPASE 7; CYTOCHROME C; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE; SERINE; STRESS ACTIVATED PROTEIN KINASE; SYNAPTOPHYSIN;

ADVANCED CANCER; ANIMAL CELL; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CANCER INHIBITION; CANCER STAGING; CELL ACTIVATION; CELL ASSAY; CELL NUCLEUS; CELL PROLIFERATION; CELL STRAIN HEPG2; CELL SURVIVAL; CELL VIABILITY; CONTROLLED STUDY; DYSPLASIA; ENZYME INHIBITION; ENZYME LINKED IMMUNOSORBENT ASSAY; ENZYME LOCALIZATION; ENZYME PHOSPHORYLATION; ENZYME RELEASE; GENE OVEREXPRESSION; GENETIC TRANSFECTION; HEPATOMA CELL; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; LIVER CELL; LIVER CELL CARCINOMA; MOUSE; NONHUMAN; PROTEIN FUNCTION; SCID MOUSE; SIGNAL TRANSDUCTION; STROMA CELL; TUMOR GROWTH; TUMOR VOLUME; WESTERN BLOTTING;

ANIMALS; APOPTOSIS; CARCINOMA, HEPATOCELLULAR; CELL LINE, TUMOR; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; HUMANS; LIVER NEOPLASMS; MICE; MICE, SCID; MITOGEN-ACTIVATED PROTEIN KINASE KINASES; MITOGEN-ACTIVATED PROTEIN KINASES; PHOSPHORYLATION;

EID: 2542473135     PISSN: 1471230X     EISSN: 1471230X     Source Type: Journal    
DOI: 10.1186/1471-230X-3-19     Document Type: Article

References (67)

1. Hussain SA, Ferry DR, El Gazzaz G, Mirza DF, James ND, McMaster P, Kerr DJ: Hepatocellular carcinoma. ann oncol 2001, 12:161-172.
2. Ince N, Wands JR: The increasing incidence of hepatocellular carcinoma. N Engl J Med 1999, 340:798-799.
3. Okuda K, Ohtsuki T, Obata H, Tomimatsu M, Okazaki N, Hasegawa H, Nakajima Y, Ohnishi K: Natural history of hepatocellular carcinoma and prognosis in relation to treatment. Study of 850 patients. Cancer 1985, 56:918-928.
4. Lai EC, Fan ST, Lo CM, Chu KM, Liu CL, Wong J: Hepatic resection for hepatocellular carcinoma. An audit of 343 patients. Ann Surg 1995, 221:291-298.
5. Takenaka K, Kawahara N, Yamamoto K, Kajiyama K, Maeda T, Itasaka H, Shirabe K, Nishizaki T, Yanaga K, Sugimachi K: Results of 280 liver resections for hepatocellular carcinoma. Arch Surg 1996, 131:71-76.
6. Huguet CSFaGA: Primary hepatocellular cancer: Western experience. In: Surgery of the Liver and Billary Tract Edited by: Blumgart L. London: Churchill Livingstone; 2000:1365-1369.
7. Lai EaWJ: Hepatocellular carcinoma: the Asian experience. In: Surgery of the Liver and the Biliary Tract Edited by: Blumgart L. London: Churchill Livingstone; 1994:1349-1363.
8. Chan ES, Chow PK, Tai B, Machin D, Soo K: Neoadjuvant and adjuvant therapy for operable hepatocellular carcinoma. Cochrane Database Syst Rev 2000:CD001199.
9. Zeng JZ, Wang HY, Chen ZJ, Ullrich A, Wu MC: Molecular cloning and characterization of a novel gene which is highly expressed in hepatocellular carcinoma. Oncogene 2002, 21:4932-4943.
10. Huynh H, Chow PK, Ooi LL, Soo KC: A possible role for insulin-like growth factor-binding protein-3 autocrine/paracrine loops in controlling hepatocellular carcinoma cell proliferation. Cell Growth Differ 2002, 13:115-122.
11. Lewis TS, Shapiro PS, Ahn NG: Signal transduction through MAP kinase cascades. Adv Cancer Res 1998, 74:49-139.
12. Ballif BA, Blenis J: Molecular mechanisms mediating mammalian mitogen-activated protein kinase (MAPK) kinase (MEK)-MAPK cell survival signals. Cell Growth Differ 2001, 12:397-408.
13. Hoshino R, Chatani Y, Yamori T, Tsuruo T, Oka H, Yoshida O, Shimada Y, Ari-i S, Wada H, Fujimoto J, Kohno M: Constitutive activation of the 41-/43-kDa mitogen-activated protein kinase signaling pathway in human tumors. Oncogene 1999, 18:813-822.
14. Amundadottir LT, Leder P: Signal transduction pathways activated and required for mammary carcinogenesis in response to specific oncogenes. Oncogene 1998, 16:737-746.
15. Krueger JS, Keshamouni VG, Atanaskova N, Reddy KB: Temporal and quantitative regulation of mitogen-activated protein kinase (MAPK) modulates cell motility and invasion. Oncogene 2001, 20:4209-4218.
16. Cowley S, Paterson H, Kemp P, Marshall CJ: Activation of MAP kinase kinase is necessary and sufficient for PC12 differentiation and for transformation of NIH 3T3 cells. Cell 1994, 77:841-852.
17. Mansour SJ, Matten WT, Hermann AS, Candia JM, Rong S, Fukasawa K, Vande Woude GF, Ahn NG: Transformation of mammalian cells by constitutively active MAP kinase kinase. Science 1994, 265:966-970.
18. Montesano R, Soriano JV, Hosseini G, Pepper MS, Schramek H: Constitutively active mitogen-activated protein kinase kinase MEK1 disrupts morphogenesis and induces an invasive phenotype in Madin-Darby canine kidney epithelial cells. Cell Growth Differ 1999, 10:317-332.
19. Dudley DT, Pang L, Decker SJ, Bridges AJ, Saltiel AR: A synthetic inhibitor of the mitogen-activated protein kinase cascade. Proc Natl Acad Sci U S A 1995, 92:7686-7689.
20. Favata MF, Horiuchi KY, Manos EJ, Daulerio AJ, Stradley DA, Feeser WS, Van Dyk DE, Pitts WJ, Earl RA, Hobbs F, Copeland RA, Magolda RL, Scherle PA, Trzaskos JM: Identification of a novel inhibitor of mitogen-activated protein kinase kinase. J Biol Chem 1998, 273:18623-18632.
21. Liu E, Thant AA, Kikkawa F, Kurata H, Tanaka S, Nawa A, Mizutani S, Matsuda S, Hanafusa H, Hamaguchi M: The Ras-mitogen-activated protein kinase pathway is critical for the activation of matrix metalloproteinase secretion and the invasiveness in v-crk-transformed 3Y1. Cancer Res 2000, 60:2361-2364.
22. Reddy KB, Krueger JS, Kondapaka SB, Diglio CA: Mitogen-activated protein kinase (MAPK) regulates the expression of progelatinase B (MMP-9) in breast epithelial cells. Int J Cancer 1999, 82:268-273.
23. Chen Y, Lu Q, Schneeberger EE, Goodenough DA: Restoration of tight junction structure and barrier function by down-regulation of the mitogen-activated protein kinase pathway in ras- transformed Madin-Darby canine kidney cells. Mol Biol Cell 2000, 11:849-862.
24. Lu Q, Paredes M, Zhang J, Kosik KS: Basal extracellular signalregulated kinase activity modulates cell-cell and cell-matrix interactions. Mol Cell Biol 1998, 18:3257-3265.
25. Mitsui H, Takuwa N, Maruyama T, Maekawa H, Hirayama M, Sawatari T, Hashimoto N, Takuwa Y, Kimura S: The MEK1-ERK map kinase pathway and the PI 3-kinase-Akt pathway independently mediate anti-apoptotic signals in HepG2 liver cancer cells. Int J Cancer 2001, 92:55-62.
26. Anderson NG, Maller JL, Tonks NK, Sturgill TW: Requirement for integration of signals from two distinct phosphorylation pathways for activation of MAP kinase. Nature 1990, 343:651-653.
27. Schmidt CM, McKillop IH, Cahill PA, Sitzmann JV: Increased MAPK expression and activity in primary human hepatocellular carcinoma. Biochem Biophys Res Commun 1997, 236:54-58.
28. Lewis TS, Hunt JB, Aveline LD, Jonscher KR, Louie DF, Yeh JM, Nahreini TS, Resing KA, Ahn NG: Identification of novel MAP kinase pathway signaling targets by functional proteomics and mass spectrometry. Mol Cell 2000, 6:1343-1354.
29. Sebolt-Leopold JS, Dudley DT, Herrera R, Van Becelaere K, Wiland A, Gowan RC, Tecle H, Barrett SD, Bridges A, Przybranowski S, Leopold WR, Saltiel AR: Blockade of the MAP kinase pathway suppresses growth of colon tumors in vivo. Nat Med 1999, 5:810-816.
30. Alessi DR, Cuenda A, Cohen P, Dudley DT, Saltiel AR: PD 098059 is a specific inhibitor of the activation of mitogen- activated protein kinase kinase in vitro and in vivo. J Biol Chem 1995, 270:27489-27494.
31. Sebolt-Leopold JS: Development of anticancer drugs targeting the MAP kinase pathway. Oncogene 2000, 19:6594-6599.
32. Spiessl B, Beahrs OH, Hermanek P, Hutter RVP, Scheibe O, Sobin LH, Wagner G: TNM - Atlas. Illustrated Guide to the TNM/pTNM Classification of Malignant Tumours. 104-111. 1992. Springer Verlag, Berlin Heidelberg New York 1989:357.
33. Ishak KG, Goodman ZD, Stocker JT: Tumors of the liver and intrahepatic bile. Atlas of tumor pathology, Third Series. Armed Forces Institute of Pathology 2001:199-230.
34. Lim IJ, Phan TT, Song C, Tan WT, Longaker MT: Investigation of the influence of keloid-derived keratinocytes on fibroblast growth and proliferation in vitro. Plast Reconstr Surg 2001, 107:797-808.
35. Gewies A, Rokhlin OW, Cohen MB: Cytochrome c is involved in Fas-mediated apoptosis of prostatic carcinoma cell lines. Cancer Res 2000, 60:2163-2168.
36. Green DR, Reed JC: Mitochondria and apoptosis. Science 1998, 281:1309-1312.
37. Cai J, Yang J, Jones DP: Mitochondrial control of apoptosis: the role of cytochrome c. Biochim Biophys Acta 1998, 1366:139-149.
38. Zou H, Li Y, Liu X, Wang X: An APAF-1.cytochrome c multimeric complex is a functional apoptosome that activates procaspase-9. J Biol Chem 1999, 274:11549-11556.
39. Cohen GM: Caspases: the executioners of apoptosis. Biochem J 1997, 326(Pt 1):1-16.
40. MacKeigan JP, Collins TS, Ting JP: MEK inhibition enhances paclitaxel-induced tumor apoptosis. J Biol Chem 2000, 275:38953-38956.
41. Wang X, Martindale JL, Holbrook NJ: Requirement for ERK activation in cisplatin-induced apoptosis. J Biol Chem 2000, 275:39435-39443.
42. Lobenhofer EK, Huper G, Iglehart JD, Marks JR: Inhibition of mitogen-activated protein kinase and phosphatidylinositol 3-kinase activity in MCF-7 cells prevents estrogen-induced mitogenesis. Cell Growth Differ 2000, 11:99-110.
43. Hii CS, Ferrante A, Edwards YS, Huang ZH, Hartfield PJ, Rathjen DA, Poulos A, Murray AW: Activation of mitogen-activated protein kinase by arachidonic acid in rat liver epithelial WB cells by a protein kinase C-dependent mechanism. J Biol Chem 1995, 270:4201-4204.
44. Kim YC, Song KS, Yoon G, Nam MJ, Ryu WS: Activated ras oncogene collaborates with HBx gene of hepatitis B virus to transform cells by suppressing HBx-mediated apoptosis. Oncogene 2001, 20:16-23.
45. Chung YH, Kim JA, Song BC, Lee GC, Koh MS, Lee YS, Lee SG, Suh DJ: Expression of transforming growth factor-alpha mRNA in livers of patients with chronic viral hepatitis and hepatocellular carcinoma. Cancer 2000, 89:977-982.
46. Ueki T, Fujimoto J, Suzuki T, Yamamoto H, Okamoto E: Expression of hepatocyte growth factor and its receptor c-met protooncogene in hepatocellular carcinoma. Hepatology 1997, 25:862-866.
47. Pelicci G, Lanfrancone L, Salcini AE, Romano A, Mele S, Grazia BM, Segatto O, Di Fiore PP, Pelicci PG: Constitutive phosphorylation of Shc proteins in human tumors. Oncogene 1995, 11:899-907.
48. Petit AM, Rak J, Hung MC, Rockwell P, Goldstein N, Fendly B, Kerbel RS: Neutralizing antibodies against epidermal growth factor and ErbB-2/neu receptor tyrosine kinases down-regulate vascular endothelial growth factor production by tumor cells in vitro and in vivo: angiogenic implications for signal transduction therapy of solid tumors. Am J Pathol 1997, 151:1523-1530.
49. Eliceiri BP, Klemke R, Stromblad S, Cheresh DA: Integrin alphavbeta3 requirement for sustained mitogen-activated protein kinase activity during angiogenesis. J Cell Biol 1998, 140:1255-1263.
50. Marshall CJ: ERK/MAP kinase kinase kinase, ERK/MAP kinase kinase, and ERK/MAP kinase. Curr Opin Genet Dev 1994, 4:82-89.
51. Seger R, Krebs EG: The MAPK signaling cascade. FASEB J 1995, 9:726-735.
52. Morishima-Kawashima M, Kosik KS: The pool of map kinase associated with microtubules is small but constitutively active. Mol Biol Cell 1996, 7:893-905.
53. Klemke RL, Cai S, Giannini AL, Gallagher PJ, de Lanerolle P, Cheresh DA: Regulation of cell motility by mitogen-activated protein kinase. J Cell Biol 1997, 137:481-492.
54. Mandell JW, Hussaini IM, Zecevic M, Weber MJ, VandenBerg SR: In situ visualization of intratumor growth factor signaling: immunohistochemical localization of activated ERK/MAP kinase in glial neoplasms. Am J Pathol 1998, 153:1411-1423.
55. Lotem J, Sachs L: Regulation of bcl-2, bcl-XL and bax in the control of apoptosis by hematopoietic cytokines and dexamethasone. Cell Growth Differ 1995, 6:647-653.
56. Fan HY, Tong C, Lian L, Li SW, Gao WX, Cheng Y, Chen DY, Schatten H, Sun QY: Characterization of Ribosomal S6 Protein Kinase p90rsk During Meiotic Maturation and Fertilization in Pig Oocytes: Mitogen-Activated Protein Kinase-Associated Activation and Localization. Biol Reprod 2003, 68:968-977.
57. Wade CB, Dorsa DM: Estrogen activation of cyclic adenosine 5′-monophosphate response element-mediated transcription requires the extracellularly regulated kinase/mitogenactivated protein kinase pathway. Endocrinol 2003, 144:832-838.
58. Boglari G, Szeberenyi J: Nuclear translocation of p90Rsk and phosphorylation of CREB is induced by ionomycin in a Ras-independent manner in PC12 cells. Acta Biol Hung 2002, 53:325-334.
59. Brognard J, Dennis PA: Variable apoptotic response of NSCLC cells to inhibition of the MEK/ERK pathway by small molecules or dominant negative mutants. Cell Death Differ 2002, 9:893-904.
60. Sautin YY, Crawford JM, Svetlov SI: Enhancement of survival by LPA via Erk1/Erk2 and PI 3-kinase/Akt pathways in a murine hepatocyte cell line. Am J Physiol Cell Physiol 2001, 21:C210-C2019.
61. Bertolotto C, Maulon L, Filippa N, Baier G, Auberger P: Protein kinase C theta and epsilon promote T-cell survival by a rsk-dependent phosphorylation and inactivation of BAD. J Biol Chem 2000, 275:37246-37250.
62. Franke TF, Yang SI, Chan TO, Datta K, Kazlauskas A, Morrison DK, Kaplan DR, Tsichlis PN: The protein kinase encoded by the Akt proto-oncogene is a target of the PDGF-activated phosphatidylinositol 3-kinase. Cell 1995, 81:727-736.
63. Page C, Lin HJ, Jin Y, Castle VP, Nunez G, Huang M, Lin J: Overexpression of Akt/AKT can modulate chemotherapy-induced apoptosis. Anticancer Res 2000, 20:407-416.
64. Almeida EA, Ilic D, Han Q, Hauck CR, Jin F, Kawakatsu H, Schlaepfer DD, Damsky CH: Matrix survival signaling: from fibronectin via focal adhesion kinase to c-Jun NH(2)-terminal kinase. J Cell Biol 2000, 149:741-754.
65. Muzio M, Stockwell BR, Stennicke HR, Salvesen GS, Dixit VM: An induced proximity model for caspase-8 activation. J Biol Chem 1998, 273:2926-2930.
66. Cryns V, Yuan J: Proteases to die for. Genes Dev 1998, 12:1551-1570.
67. Germain M, Affar EB, D'Amours D, Dixit VM, Salvesen GS, Poirier GG: Cleavage of automodified poly(ADP-ribose) polymerase during apoptosis. Evidence for involvement of caspase-7. J Biol Chem 1999, 274:28379-28384.